Epigenetic Regulation of the Human Retinoblastoma Tumor Suppressor Gene Promoter by CTCF
Authors:
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (6) , 2577-2585
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and are caused by activating mutations of the KIT or platelet-derived growth factor receptor α (PDGFRA) tyrosine kinases. GISTs can be successfully treated with imatinib mesylate, a selective small-molecule protein kinase inhibitor that was first clinically approved to target the oncogenic BCR-ABL fusion protein kinase in chronic myelogenous leukemia, but which also potently inhibits KIT and PDGFR family members. The mechanistic events by which KIT/PDGFRA kinase inhibition leads to clinical responses in GIST patients are not known in detail. We report here that imatinib triggers GIST cell apoptosis in part through the up-regulation of soluble histone H2AX, a core histone H2A variant. We found that untreated GIST cells down-regulate H2AX in a pathway that involves KIT, phosphoinositide-3-kinase, and the ubiquitin/proteasome machinery, and that the imatinib-mediated H2AX up-regulation correlates with imatinib sensitivity. Depletion of H2AX attenuated the apoptotic response of GIST cells to imatinib. Soluble H2AX was found to sensitize GIST cells to apoptosis by aberrant chromatin aggregation and a transcriptional block. Our results underscore the importance of H2AX as a human tumor suppressor protein, provide mechanistic insights into imatinib-induced tumor cell apoptosis and establish H2AX as a novel target in cancer therapy. [Cancer Res 2007;67(6):2685–92]Keywords
This publication has 82 references indexed in Scilit:
- Epigenetic boundaries of tumour suppressor gene promoters: the CTCF connection and its role in carcinogenesisJournal of Cellular and Molecular Medicine, 2006
- Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nature Reviews Cancer, 2006
- The epigenetic progenitor origin of human cancerNature Reviews Genetics, 2006
- Footprinting the ‘essential regulatory region’ of the retinoblastoma gene promoter in intact human cellsThe International Journal of Biochemistry & Cell Biology, 2005
- CpG island methylator phenotype in cancerNature Reviews Cancer, 2004
- Poly(ADP-ribosyl)ation and Epigenetics: Is CTCF PARt of the Plot?Cell Cycle, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004
- The Binding Sites for the Chromatin Insulator Protein CTCF Map to DNA Methylation-Free Domains Genome-WideGenome Research, 2004
- Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular SenescenceCell, 2003
- MyoD Stimulates RB Promoter Activity via the CREB/p300 Nuclear Transduction PathwayMolecular and Cellular Biology, 2003